Details for Patent: 11,497,745
✉ Email this page to a colleague
Which drugs does patent 11,497,745 protect, and when does it expire?
Patent 11,497,745 protects LIVMARLI and is included in one NDA.
This patent has thirty-two patent family members in ten countries.
Drugs Protected by US Patent 11,497,745
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) | ⤷ Subscribe | ||||
| Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS) | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,497,745
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020221239 | ⤷ Subscribe | |||
| Australia | 2020221834 | ⤷ Subscribe | |||
| Australia | 2020223022 | ⤷ Subscribe | |||
| Brazil | 112021015799 | ⤷ Subscribe | |||
| Brazil | 112021015809 | ⤷ Subscribe | |||
| Brazil | 112021015815 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
